Impact of Auditory Integrative Training on Transforming Growth Factor-β1 and Its Effect on Behavioral and Social Emotions in Children with Autism Spectrum Disorder

Overview

Journal Med Princ Pract

Publisher Karger

Specialties General Medicine
Medical Education

Date 2018 Jan 4

PMID 29298441

Citations 4

Authors

Laila Al-Ayadhi

Abdulrahman Mohammed Alhowikan

Dost Muhammad Halepoto

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the impact of auditory integrative training (AIT) on the inflammatory biomarker transforming growth factor (TGF)-β1 and to assess its effect on social behavior in children with autism spectrum disorder (ASD).

Subjects And Methods: In this cross-sectional study, 15 patients (14 males and 1 female) with ASD aged 3-12 years were recruited. All were screened for autism using the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Plasma levels of TGF-β1 were measured in all patients using a sandwich enzyme-linked immunoassay (ELISA) immediately and 1 and 3 months after the AIT sessions. Pre- and post-AIT behavioral scores were also calculated for each child using the Childhood Autism Rating Scale (CARS), the Social Responsiveness Scale (SRS), and the Short Sensory Profile (SSP). Data were analyzed using the Statistical Package for the Social Sciences (SPSS 21.0 for Windows).

Results: Plasma levels of TGF-β1 significantly increased to 85% immediately after AIT (20.13 ± 12 ng/mL, p < 0.05), to 95% 1 month after AIT (21.2 ± 11 ng/mL, p < 0.01), and to 105% 3 months after AIT (22.25 ± 16 ng/mL, p < 0.01) compared to before AIT (10.85 ± 8 ng/mL). Results also revealed that behavioral rating scales (CARS, SRS, and SSP) improved in terms of disease severity after AIT.

Conclusion: Increased plasma levels of TGF-β1 support the therapeutic effect of AIT on TGF-β1 followed by improvement in social awareness, social cognition, and social communication in children with ASD. Furthermore, TGF-β1 was associated with severity in all scores tested (CARS, SRS, and SSP); if confirmed in studies with larger sample sizes, TGF-β1 may be considered as a marker of ASD severity and to assess the efficacy of therapeutic interventions.

Citing Articles

The possible link between Fetuin-A Protein and Neuro-inflammation in Children with Autism Spectrum Disorder.

Al-Ayadhi L, Alghamdi F, Altamimi L, Alsughayer L, Alhowikan A, Halepoto D Pak J Med Sci. 2021; 37(4):1166-1171.

PMID: 34290802 PMC: 8281191. DOI: 10.12669/pjms.37.4.4032.

The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.

Zheng Y, Verhoeff T, Pardo P, Garssen J, Kraneveld A Int J Mol Sci. 2020; 22(1).

PMID: 33374371 PMC: 7796333. DOI: 10.3390/ijms22010118.

Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets.

Baranova J, Dragunas G, Botellho M, Ayub A, Bueno-Alves R, Alencar R Cell Mol Neurobiol. 2020; 41(4):619-649.

PMID: 32468442 PMC: 11448616. DOI: 10.1007/s10571-020-00882-7.

Rapid Communication: Plasma Interleukin-35 in Children with Autism.

Rose D, Ashwood P Brain Sci. 2019; 9(7).

PMID: 31252635 PMC: 6680732. DOI: 10.3390/brainsci9070152.

References

Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen L . Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 2008; 204(1-2):149-53. PMC: 2615583. DOI: 10.1016/j.jneuroim.2008.07.006. View

Pfeiffer B, Koenig K, Kinnealey M, Sheppard M, Henderson L . Effectiveness of sensory integration interventions in children with autism spectrum disorders: a pilot study. Am J Occup Ther. 2011; 65(1):76-85. PMC: 3708964. DOI: 10.5014/ajot.2011.09205. View

El-Ansary A, Hassan W, Qasem H, Das U . Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. PLoS One. 2016; 11(11):e0164153. PMC: 5100977. DOI: 10.1371/journal.pone.0164153. View

Coccaro E, Lee R, Coussons-Read M . Cerebrospinal fluid inflammatory cytokines and aggression in personality disordered subjects. Int J Neuropsychopharmacol. 2015; 18(7):pyv001. PMC: 4540103. DOI: 10.1093/ijnp/pyv001. View

Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya K . Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(1):187-90. DOI: 10.1016/j.pnpbp.2006.08.020. View

Zhang G, Gong Q, Zhang F, Chen S, Hu L, Liu F . [Effects of auditory integrative training on autistic children]. Beijing Da Xue Xue Bao Yi Xue Ban. 2009; 41(4):426-31. View

Paul R . Interventions to improve communication in autism. Child Adolesc Psychiatr Clin N Am. 2008; 17(4):835-56, ix-x. PMC: 2635569. DOI: 10.1016/j.chc.2008.06.011. View

Sokhadze E, Casanova M, Tasman A, Brockett S . Electrophysiological and Behavioral Outcomes of Berard Auditory Integration Training (AIT) in Children with Autism Spectrum Disorder. Appl Psychophysiol Biofeedback. 2016; 41(4):405-420. DOI: 10.1007/s10484-016-9343-z. View

Constantino J, Davis S, Todd R, Schindler M, Gross M, Brophy S . Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord. 2003; 33(4):427-33. DOI: 10.1023/a:1025014929212. View

10.

Prehn J, Backhauss C, Krieglstein J . Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J Cereb Blood Flow Metab. 1993; 13(3):521-5. DOI: 10.1038/jcbfm.1993.67. View

11.

Perry A, Condillac R, Freeman N, Dunn-Geier J, Belair J . Multi-site study of the Childhood Autism Rating Scale (CARS) in five clinical groups of young children. J Autism Dev Disord. 2005; 35(5):625-34. DOI: 10.1007/s10803-005-0006-9. View

12.

Khakzad M, Salari F, Javanbakht M, Hojati M, Varasteh A, Sankian M . Transforming growth factor beta 1 869T/C and 915G/C polymorphisms and risk of autism spectrum disorders. Rep Biochem Mol Biol. 2016; 3(2):82-8. PMC: 4757046. View

13.

Wyss-Coray T, Borrow P, Brooker M, Mucke L . Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice . J Neuroimmunol. 1997; 77(1):45-50. DOI: 10.1016/s0165-5728(97)00049-0. View

14.

Bjorklund G, Saad K, Chirumbolo S, Kern J, Geier D, Geier M . Immune dysfunction and neuroinflammation in autism spectrum disorder. Acta Neurobiol Exp (Wars). 2017; 76(4):257-268. DOI: 10.21307/ane-2017-025. View

15.

Tager-Flusberg H, Kasari C . Minimally verbal school-aged children with autism spectrum disorder: the neglected end of the spectrum. Autism Res. 2013; 6(6):468-78. PMC: 3869868. DOI: 10.1002/aur.1329. View

16.

Sinha Y, Silove N, Wheeler D, Williams K . Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. Arch Dis Child. 2006; 91(12):1018-22. PMC: 2082994. DOI: 10.1136/adc.2006.094649. View

17.

Vargas D, Nascimbene C, Krishnan C, Zimmerman A, Pardo C . Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2004; 57(1):67-81. DOI: 10.1002/ana.20315. View

18.

Kulkarni A, Huh C, Becker D, Geiser A, Lyght M, Flanders K . Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90(2):770-4. PMC: 45747. DOI: 10.1073/pnas.90.2.770. View

19.

Aihara K, Ikeda Y, Yagi S, Akaike M, Matsumoto T . Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract. 2011; 2011:175381. PMC: 3018616. DOI: 10.4061/2011/175381. View

20.

Kohane I, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L . The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One. 2012; 7(4):e33224. PMC: 3325235. DOI: 10.1371/journal.pone.0033224. View